Rossari Biotech Ltd (IN:ROSSARI)
:ROSSARI
Want to see IN:ROSSARI full AI Analyst Report?
Top Page
Rossari Biotech Ltd
(ROSSARI)
Select Model
Select Model
Rating:64Neutral
Price Target:
₹577.00
▼(-1.19% Downside)
Action:Reiterated
Date:05/08/26
The score is held back primarily by weak cash flow quality (volatile operating cash flow and persistently negative free cash flow) alongside weakening 2026 margins and rising debt, despite supportive valuation (low P/E and dividend yield) and improving near-term technical momentum.
Positive Factors
Sustained revenue growth
Consistent multi-year revenue expansion indicates durable commercial traction across product lines and end markets. This steady top-line base supports scale economies, predictable B2B recurring sales, and provides a foundation for reinvestment and cross-selling over the next 2–6 months and beyond.
Negative Factors
Weak cash generation
Persistently negative and volatile cash conversion undermines internal funding for capex and working capital. Over 2–6 months this reduces flexibility, raises refinancing risk, and forces reliance on external funding or higher borrowing costs, constraining strategic options.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue growth
Consistent multi-year revenue expansion indicates durable commercial traction across product lines and end markets. This steady top-line base supports scale economies, predictable B2B recurring sales, and provides a foundation for reinvestment and cross-selling over the next 2–6 months and beyond.
Read all positive factors
Rossari Biotech Ltd (ROSSARI) vs. iShares MSCI India ETF (INDA)
Market Cap
₹28.10B
Dividend Yield0.09%
Average Volume (3M)2.66K
Price to Earnings (P/E)11.4
Beta (1Y)0.94
Revenue Growth15.19%
EPS Growth9.27%
CountryIN
Employees450
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)24.68
Shares Outstanding55,383,366
10 Day Avg. Volume1,386
30 Day Avg. Volume2,661
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)1.57
Price to Sales (P/S)0.87
P/FCF Ratio-9.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)32.36
Revenue Forecast (FY)₹26.68B
Rossari Biotech Ltd Business Overview & Revenue Model
Company Description
Rossari Biotech Limited engages in manufacture and sale of specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; and water treatment solutions. The...
How the Company Makes Money
Rossari Biotech primarily makes money by selling specialty chemical products and formulations to other businesses (B2B). Revenue is generated through: (1) Product sales across its key end-user segments—where the company supplies application-specif...
Rossari Biotech Ltd Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.22B | 23.96B | 20.80B | 18.31B | 16.56B | 14.83B |
| Gross Profit | 6.42B | 4.94B | 6.47B | 5.26B | 2.80B | 2.29B |
| EBITDA | 2.77B | 2.86B | 2.65B | 2.57B | 2.12B | 1.94B |
| Net Income | 1.37B | 1.49B | 1.36B | 1.31B | 1.07B | 976.74M |
Balance Sheet | ||||||
| Total Assets | 20.88B | 22.89B | 18.96B | 15.72B | 13.68B | 12.57B |
| Cash, Cash Equivalents and Short-Term Investments | 719.76M | 1.27B | 1.14B | 667.85M | 1.52B | 644.26M |
| Total Debt | 3.53B | 4.36B | 2.18B | 1.19B | 739.28M | 84.27M |
| Total Liabilities | 8.36B | 9.55B | 7.11B | 5.24B | 4.52B | 4.52B |
| Stockholders Equity | 12.51B | 13.33B | 11.85B | 10.48B | 9.15B | 8.05B |
Cash Flow | ||||||
| Free Cash Flow | -1.67B | -2.20B | -210.69M | -880.28M | 1.20B | -88.67M |
| Operating Cash Flow | -250.32M | 451.63M | 1.37B | 432.55M | 1.52B | 293.58M |
| Investing Cash Flow | -1.06B | -2.22B | -1.84B | -1.03B | -1.81B | -2.99B |
| Financing Cash Flow | 1.22B | 2.09B | 649.01M | 161.85M | 608.55M | 2.92B |
Rossari Biotech Ltd Technical Analysis
Neutral
583.95
Price Trends
467.73
Positive
503.97
Positive
569.41
Negative
Market Momentum
10.68
Positive
53.41
Neutral
24.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ROSSARI, the sentiment is Neutral. The current price of 583.95 is above the 20-day moving average (MA) of 505.20, above the 50-day MA of 467.73, and above the 200-day MA of 569.41, indicating a neutral trend. The MACD of 10.68 indicates Positive momentum. The RSI at 53.41 is Neutral, neither overbought nor oversold. The STOCH value of 24.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ROSSARI.
Rossari Biotech Ltd Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹39.74B | 17.65 | ― | 0.65% | 44.79% | 14.20% | |
66 Neutral | ₹59.22B | 18.92 | ― | 0.97% | 2.00% | 7.14% | |
64 Neutral | ₹28.10B | 11.40 | ― | 0.09% | 15.19% | 9.27% | |
63 Neutral | ₹64.75B | 20.08 | ― | 1.07% | 24.26% | -12.32% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
57 Neutral | ₹23.58B | 0.22 | ― | ― | -19.38% | 1266.07% | |
53 Neutral | ₹29.06B | 51.39 | ― | 0.07% | 32.18% | 636.02% |
* Basic Materials Sector Average
IN:ROSSARI
Rossari Biotech Ltd
507.45
-148.75
-22.67%
IN:BALAMINES
Balaji Amines Limited
1,827.85
395.86
27.64%
IN:FCL
Fineotex Chemical Limited
34.13
11.05
47.88%
IN:GALAXYSURF
Galaxy Surfactants Ltd.
1,826.25
-390.71
-17.62%
IN:KIRIINDUS
Kiri Industries Limited
392.80
-273.80
-41.07%
IN:TATVA
Tatva Chintan Pharma Chem Limited
1,242.45
276.81
28.67%
Rossari Biotech Ltd Corporate Events
Rossari Biotech Publishes FY26 Audited Results Extracts in Financial Dailies
Apr 28, 2026
Rossari Biotech Ltd has announced that it has published an extract of its consolidated audited financial results for the quarter and full financial year ended 31 March 2026 in two newspapers, Financial Express (English) and Loksatta (Marathi), bot...
Rossari Biotech posts record Q4 and steady FY26 growth despite margin pressure
Apr 28, 2026
Rossari Biotech reported its highest-ever quarterly performance in Q4 FY26, with consolidated revenue from operations rising 18% year-on-year to Rs 684.9 crore and EBITDA increasing 11% to Rs 77.3 crore, although the EBITDA margin softened slightl...
Rossari Biotech Reschedules Subsidiaries’ Capacity Expansion in Phased Rollout
Apr 23, 2026
Rossari Biotech has announced that its material subsidiaries, Unitop Chemicals and Tristar Intermediates, are re-evaluating their previously disclosed capacity expansion plans in response to changing business requirements and market conditions. As...
Rossari Biotech to Host Q4 FY26 Earnings Call on April 28
Apr 21, 2026
Rossari Biotech Ltd has scheduled an earnings conference call for investors and analysts on Tuesday, April 28, 2026, at 5:00 p.m. IST to discuss its financial results for the fourth quarter and full year ended March 31, 2026. The call will open wi...
Rossari Subsidiary Unitop Chemicals to Sell Non-Core Mumbai Office for Rs 10 Crore
Apr 3, 2026
Rossari Biotech has disclosed that the board of its material subsidiary, Unitop Chemicals Private Limited, has approved the sale of an office premises in Saki Naka, Mumbai, for approximately Rs 10 crore. The transaction is expected to be completed...
Rossari Biotech Renames Dubai Subsidiary to Comply With DMCC Norms
Mar 24, 2026
Rossari Biotech has announced that its wholly owned subsidiary Rossari Global DMCC has changed its name to Rossari Global FZCO, effective March 23, 2026, following a certificate issued by the Dubai Multi Commodities Centre Authority. The change is...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.